Literature DB >> 24922497

Clinical staging in bipolar disorder: focus on cognition and functioning.

Adriane R Rosa1, Pedro V S Magalhães, Letícia Czepielewski, Miréia Viana Sulzbach, Pedro D Goi, Eduard Vieta, Clarissa S Gama, Flávio Kapczinski.   

Abstract

OBJECTIVE: Clinical staging has increasingly been considered suitable for psychiatric disorders such as bipolar disorder. A staging model of bipolar disorder could help clinicians understand the mechanisms underlying the course of the illness and guide prognosis and therapy. This study aimed to investigate differences in functional status and cognitive functioning in patients in different clinical stages of bipolar disorder.
METHOD: Subjects who met DSM-IV criteria for bipolar disorder (n = 54) were recruited from the Bipolar Disorders Program at Hospital de Clínicas de Porto Alegre (Brazil) from October 2012 to October 2013. All patients had been in remission (score < 7 on the 17-item HDRS and the YMRS) for at least 1 month before assessment. They were classified into 4 clinical stages according to the model described by Kapczinski et al and compared to 43 healthy controls. Functional status was assessed by using the Functioning Assessment Short Test (FAST). Neuropsychological measures were performed to investigate cognitive functioning.
RESULTS: Significant differences in functional status were found between patients in all stages compared to controls (F = 33.014, P < .001), except for stage I (P = .104). Additionally, a very strong linear association was found between FAST scores and clinical stages, with FAST scores increasing from stage I to IV (F = 149.55, P < .001). In the bipolar group, stage I was associated with better occupational functioning than stage II (F = 48.344, P = .003). Stage IV patients experienced greater impairment in autonomy than stage III patients (F = 26.646, P = .004), and stage III patients experienced poorer autonomy than those in stage II (P = .004). With regard to cognitive measures, patients in late stages (stages III and IV) were more impaired than healthy controls (P < .001). A similar performance was found between patients in early stages (stages I and II) and healthy controls. DISCUSSION: This study showed progressive functional changes from stage I to stage IV of bipolar disorder, with a greater impairment in patients in later stages of the illness. FAST scores seem to have a good discriminant ability to distinguish between patients in early versus late stages of bipolar disorder and could therefore contribute to the development of a bipolar disorder staging system. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24922497     DOI: 10.4088/JCP.13m08625

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  41 in total

1.  TSPO upregulation in bipolar disorder and concomitant downregulation of mitophagic proteins and NLRP3 inflammasome activation.

Authors:  Giselli Scaini; Tatiana Barichello; Gabriel R Fries; Elizabeth A Kennon; Taylor Andrews; Bobby R Nix; Giovana Zunta-Soares; Samira S Valvassori; Jair C Soares; João Quevedo
Journal:  Neuropsychopharmacology       Date:  2018-12-11       Impact factor: 7.853

Review 2.  Bipolar disorder: role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites.

Authors:  George Anderson; Michael Maes
Journal:  Curr Psychiatry Rep       Date:  2015-02       Impact factor: 5.285

Review 3.  Early interventions for youths at high risk for bipolar disorder: a developmental approach.

Authors:  Xavier Benarous; Angèle Consoli; Vanessa Milhiet; David Cohen
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-09-22       Impact factor: 4.785

4.  Staging in bipolar disorder: from theoretical framework to clinical utility.

Authors:  Michael Berk; Robert Post; Aswin Ratheesh; Emma Gliddon; Ajeet Singh; Eduard Vieta; Andre F Carvalho; Melanie M Ashton; Lesley Berk; Susan M Cotton; Patrick D McGorry; Brisa S Fernandes; Lakshmi N Yatham; Seetal Dodd
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

5.  Modifiable and non-modifiable factors associated with functional impairment during the inter-episodic periods of bipolar disorder.

Authors:  Andrea Murru; Isabella Pacchiarotti; Norma Verdolini; Maria Reinares; Carla Torrent; Pierre-Alexis Geoffroy; Frank Bellivier; Pierre-Michel Llorca; Eduard Vieta; Ludovic Samalin
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-05-22       Impact factor: 5.270

6.  Transdiagnostic clinical staging in youth mental health: a first international consensus statement.

Authors:  Jai L Shah; Jan Scott; Patrick D McGorry; Shane P M Cross; Matcheri S Keshavan; Barnaby Nelson; Stephen J Wood; Steven Marwaha; Alison R Yung; Elizabeth M Scott; Dost Öngür; Philippe Conus; Chantal Henry; Ian B Hickie
Journal:  World Psychiatry       Date:  2020-06       Impact factor: 49.548

7.  Inflammation as a Mechanism of Bipolar Disorder Neuroprogression.

Authors:  Tatiana Barichello; Vijayasree Vayalanellore Giridharan; Gursimrat Bhatti; Pavani Sayana; Tejaswini Doifode; Danielle Macedo; Joao Quevedo
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 8.  Neuroprogression and Cognitive Functioning in Bipolar Disorder: A Systematic Review.

Authors:  Taiane Cardoso; Isabelle E Bauer; Thomas D Meyer; Flavio Kapczinski; Jair C Soares
Journal:  Curr Psychiatry Rep       Date:  2015-09       Impact factor: 5.285

9.  A cluster analytic approach to identifying predictors and moderators of psychosocial treatment for bipolar depression: Results from STEP-BD.

Authors:  Thilo Deckersbach; Amy T Peters; Louisa G Sylvia; Alexandra K Gold; Pedro Vieira da Silva Magalhaes; David B Henry; Ellen Frank; Michael W Otto; Michael Berk; Darin D Dougherty; Andrew A Nierenberg; David J Miklowitz
Journal:  J Affect Disord       Date:  2016-05-31       Impact factor: 4.839

10.  Association of Lipid Peroxidation and Brain-Derived Neurotrophic Factor with Executive Function in Adolescent Bipolar Disorder.

Authors:  Dwight F Newton; Melanie R Naiberg; Ana C Andreazza; Gustavo Scola; Daniel P Dickstein; Benjamin I Goldstein
Journal:  Psychopharmacology (Berl)       Date:  2016-12-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.